Arey, the Los Angeles-based beauty brand focused on dermatology-backed skincare, has closed a Series A funding round led by Unilever Ventures. The investment signals confidence in Arey's science-driven approach at a moment when clean beauty and clinical efficacy dominate consumer priorities.
The brand plans to deploy capital across three core areas: accelerating research and development, strengthening retail partnerships, and expanding clinical research initiatives. These investments position Arey to compete in an increasingly crowded prestige skincare market where brands must prove efficacy through rigorous testing and dermatologist endorsement.
Unilever Ventures, the corporate venture arm of Unilever, brings more than capital to the table. The organization invests in early-stage brands that align with Unilever's portfolio philosophy, which includes a strong emphasis on sustainability, science, and scalability. Unilever's backing carries weight with retailers and distributors, potentially opening doors for Arey beyond direct-to-consumer channels where many indie beauty brands initially gain traction.
The skincare market has fractured into distinct consumer camps. Legacy prestige brands like Estée Lauder and Shiseido compete against newer players like The Ordinary and Drunk Elephant that built followings on either affordability or wellness credentials. Arey sits in the clinical skincare space, where brands like CeraVe, Cetaphil, and prescription-adjacent lines command significant shelf space in Sephora and Ulta Beauty. The category has grown because consumers increasingly trust dermatologist recommendations over influencer hype.
Clinical research represents a major differentiator. While many beauty brands claim "dermatologist-approved," few invest substantially in peer-reviewed studies or clinical trials. This funding round allows Arey to conduct the kind of research that generates publishable results, builds credibility with dermatologists, and supports product claims that survive regulatory scrutiny.
R&D expansion matters in skincare because formulation intelligence drives competitive advantage. Brands that master ingredient sourcing, stability, and efficacy at scale command loyalty. Arey's focus on R&D suggests the brand plans to develop proprietary technologies or formulations that justify premium pricing and retail presence.
Retail partnerships have become a bottleneck for indie beauty brands. Sephora, Ulta, and department stores face brutal space constraints. Getting shelf placement requires proving sell-through rates, handling logistics, and managing wholesale economics. Unilever's distribution expertise and retailer relationships accelerate what might otherwise take years of negotiation.
This Series A also reflects broader venture appetite for beauty and personal care. While venture capital cooled across tech in 2023 and early 2024, beauty funding remained relatively robust because the category generates predictable revenue, operates with healthy margins, and taps into consumer spending that stays stable even during economic downturns. Skincare specifically attracts capital because consumers view it as self-care investment rather than discretionary luxury.
Arey enters a market where clinical storytelling drives choice. Brands succeed by publishing research, securing dermatologist endorsements, and building education around actives like retinoids, peptides, and ceramides. The brand's ability to execute on clinical credibility while maintaining contemporary marketing will determine whether this funding translates into sustained growth or becomes another well-capitalized entrant that struggles to differentiate.
The investment reflects confidence that dermatology-backed skincare remains a durable category where science beats noise.